Antisense Oligonucleotide Therapeutics-Pipeline Insight, 2021 | Analytical Research Cognizance

Antisense Oligonucleotide Therapeutics-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667922
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Antisense Oligonucleotide Therapeutics Understanding
Antisense Oligonucleotide Therapeutics: Overview
Antisense oligonucleotide (ASOs) are small-sized single-stranded nucleic acids that offer advantages over siRNAs in terms of targeting both nuclear and cytoplasmic located lncRNAs. Antisense oligonucleotide-based therapeutics involves downregulation of gene expression. Antisense oligonucleotides (AOs) are a class of synthetic nucleic acid molecules that are capable of regulating gene expression through binding to premature or mature messenger RNA (mRNA) targets. Antisense oligonucleotides (ASOs), known as genetic materials, are promising agents used in the regulation of unsuitable expression of genes in pathological situations by the specific inhibition of expression of their mRNA targets. By capitalizing “antisense” DNA approach, the overexpressed proteins can be blocked in several diseases such as cancer, neurological diseases, cardiovascular diseases, inflammation and autoimmune diseases, infectious diseases, etc. ASOs are emerging as a class of therapeutics with high potential to treat diseases affecting the CNS.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Antisense Oligonucleotide Therapeutics R&D. The therapies under development are focused on novel approaches for Antisense Oligonucleotide Therapeutics.

Antisense Oligonucleotide Therapeutics Emerging Drugs Chapters
This segment of the Antisense Oligonucleotide Therapeutics report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Antisense Oligonucleotide Therapeutics Emerging Drugs
Cobitolimod: InDex Pharmaceuticals
Cobitolimod is a Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod is a DNA-based ImmunoModulatory Sequence (DIMS) that is administered locally inside the large intestine, where it binds to Toll-like receptor 9 (TLR9) present inside immune cells as well as on the surface of epithelial cells. Cobitolimod is a first in class treatment that can provide a local anti-inflammatory effect, which can lead to healing of the mucosa and improvement of clinical symptoms. Cobitolimod is has a very limited systemic absorption. US Food and Drug Administration (FDA) has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Prexigebersen: Bio-Path Holdings
Prexigebersen (previously BP 100-1-01) is a neutral-charge, liposomal-delivered antisense cancer drug. It is designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2). Bio-Path is currently evaluating prexigebersen in Phase II program for the treatment of acute myeloid leukemia (AML). Prexigebersen has received orphan drug designation from the FDA and from the European Medicines Agency for AML.
Further product details are provided in the report……..

Antisense Oligonucleotide Therapeutics: Therapeutic Assessment
This segment of the report provides insights about the different Antisense Oligonucleotide Therapeutics drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Antisense Oligonucleotide Therapeutics
There are approx. 15+ key companies which are developing the Antisense Oligonucleotide Therapeutics. The companies which have their Antisense Oligonucleotide Therapeutics drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Antisense Oligonucleotide Therapeutics pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Antisense Oligonucleotide Therapeutics: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Antisense Oligonucleotide Therapeutics therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Antisense Oligonucleotide Therapeutics drugs.

Antisense Oligonucleotide Therapeutics Report Insights
Antisense Oligonucleotide Therapeutics Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Antisense Oligonucleotide Therapeutics Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Scenario and Emerging Therapies:
How many companies are developing Antisense Oligonucleotide Therapeutics drugs?
How many Antisense Oligonucleotide Therapeutics drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for Antisense Oligonucleotide Therapeutics?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Antisense Oligonucleotide Therapeutics therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Antisense Oligonucleotide Therapeutics and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
InDex Pharmaceuticals
Bio-Path Holdings
Akcea Therapeutics
Ionis Pharmaceuticals
AstraZeneca
Gene Signal
Chamishi Therapeutics
NeuBase Therapeutics

Key Products
Cobitolimod
Prexigebersen
Inotersen
AKCEA APOCIII LRx
ION 736
NS-089/NCNP-02
Aganirsen
Research programme : antisense oligonucleotide therapeutics
NT0100

Introduction
Executive Summary
Antisense Oligonucleotide Therapeutics: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Antisense Oligonucleotide Therapeutics – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Antisense Oligonucleotide Therapeutics companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Antisense Oligonucleotide Therapeutics Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Cobitolimod: InDex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Prexigebersen: Bio-Path Holdings
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
ION 736: Ionis Pharmaceuticals/AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NT0100: NeuBase Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Antisense Oligonucleotide Therapeutics Key Companies
Antisense Oligonucleotide Therapeutics Key Products
Antisense Oligonucleotide Therapeutics- Unmet Needs
Antisense Oligonucleotide Therapeutics- Market Drivers and Barriers
Antisense Oligonucleotide Therapeutics- Future Perspectives and Conclusion
Antisense Oligonucleotide Therapeutics Analyst Views
Antisense Oligonucleotide Therapeutics Key Companies
Appendix

Table 1 Total Products for Antisense Oligonucleotide Therapeutics
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Antisense Oligonucleotide Therapeutics
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products